Angiotensin-converting enzyme in substantia nigra: reduction of activity in Huntington's disease and after intrastriatal kainic acid in rats.
The substantia nigra of Huntington's disease brains shows a 78% reduction in angiotensin-converting enzyme activity in the pars reticulata and a 48% reduction in the pars compacta. The nucleus accumbens shows a 28% reduction in converting enzyme activity. In the rat, after intrastriatal injections of kainic acid (2.5 microgram), an agent which selectively destroys neuronal cell bodies, there is a 55% reduction in angiotensin-converting enzyme activity in the ipsilateral substantia nigra. Both human and animal data suggest that a major part of the angiotensin-converting enzyme in the substantia nigra is localized in nerve terminals whose cell bodies originate in the striatum.
D000818:Animals; D002421:Caudate Nucleus / Q000201:enzymology; D003342:Corpus Striatum / Q000187:drug effects; D006801:Humans; D006816:Huntington Disease / Q000201:enzymology*; D007608:Kainic Acid / Q000494:pharmacology*; D008297:Male; D009714:Nucleus Accumbens / Q000201:enzymology; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism*; D011699:Putamen / Q000201:enzymology; D011759:Pyrrolidines / Q000494:pharmacology*; D051381:Rats; D013378:Substantia Nigra / Q000378:metabolism*
D011759:Pyrrolidines; D007703:Peptidyl-Dipeptidase A; D007608:Kainic Acid